ClinicalTrials.gg
RecruitingNCT05495633SteamOneUpdated Oct 20, 2026

SteamOne - Prospective Database for Rezum Water Vapor Therapy of the Prostate

An observational study in Benign Prostate Obstruction (BPO), sponsored by University Hospital, Basel, Switzerland. Recruiting at 19 sites in 3 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by University Hospital, Basel, Switzerland · Observational

How we know

From the registry’s dates

  • Started Dec 2022; still recruiting 3 years 11 months later.
Updated Oct 20, 20262 sites added2 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Lower Urinary Tract Symptoms with a site in Germany — 3 open to participants now, 4 under way, none of them phase 3. Lower Urinary Tract Symptoms · Germany.

Started
2022
the only one that year
Observational
4 of 12
3 open now
Registered
10th of 12
by date
Lead sponsor
1 of 12
University Hospital, Basel, Switzerland

Among the 12 studies in Lower Urinary Tract Symptoms with a site in Germany, this one is the only one that started in 2022, is one of 4 observational ones, and was the 10th registered.

Lower Urinary Tract Symptoms

419 studies on the registry are indexed under Lower Urinary Tract Symptoms; 110 are open to participants now.

Browse Lower Urinary Tract Symptoms studies →

Open to participants now

3 of the 12 studies in Lower Urinary Tract Symptoms with a site in Germany are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 60 Lower Urinary Tract Symptoms studies recruiting now, 40 (67%) set no upper age limit and 11 (18%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Lower Urinary Tract Symptoms with a site in Germany, or all of them as a file.
02

Study summary

This study is to assess the clinical data of Rezum (water vapor therapy) in patients with BPO (benign prostate obstruction) and male LUTS (lower urinary tract symptoms) in terms of efficacy, durability and safety in a large, prospective, multi-center cohort consisting of 1000 "real-life" patients with a follow-up of 5 years.

Read the detailed description

Prostate water vapor therapy (Rezum) is an approved treatment procedure for the management of lower urinary tract symptoms in men caused by benign prostatic obstruction (BPO). Rezum is performed transurethrally by steam injections into the central or transition zone of the enlarged prostate. The 103°C hot steam is generated by a generator and injected into the prostate tissue via a disposable handpiece with a retractable needle. Approximately 1 injection is required per 10 ml of prostate tissue to achieve desobstruction. The single injection takes only 9 seconds. The thermal energy contained in the water vapor is able to develop evenly and freely in the intercellular space of the prostate by convection. This represents a unique technique in surgical desobstruction of the prostate. The steam condenses and releases the stored heat energy to the cell membranes, which then denature. As a result, the prostate tissue shrinks by about 30% in the first three months after the Rezum treatment. The shrinkage process therefore does not take place immediately, but with a time delay. The minimally invasive nature of the procedure results from the short surgical time, the potential of Rezum to preserve sexual function (both ejaculation and erection), and the possibility of performing Rezum even under local anesthesia or analgesia. Data on efficacy, durability of efficacy, safety/complications, and indication groups are still limited. "Real life" data are important to determine the role of Rezum water vapor therapy in the treatment of BPO and male LUTS. The aim of this study is to prospectively enroll and follow Rezum patients in a multicenter, German-language, web-based database. Patient-reported outcome measures (PROMs) and clinical-reported outcome measures/data (CROMs) on various subgroups of patients treated with Rezum as a routine clinical treatment option for BPO-related male LUTS will be recorded in terms of procedure efficacy, functional outcomes (e.g. sexual function) and surgical safety. Further aspects of interest are recovery from the procedure, patients' expectations towards Rezum treatment, patients' satisfaction with Rezum treatment, and impact of Rezum on quality of life.

03

Conditions studied

  • Benign Prostate Obstruction (BPO)

Keywords

  • Lower Urinary Tract Symptoms (LUTS)
  • Rezum water vapor therapy
  • prostate
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients who are treated with Rezum - water vapor therapy of the prostate due to benign prostate obstruction (BPO) or male lower urinary tract symptoms (LUTS) as part of routine clinical practice. Patients will be recruited within the participating study hospitals as part of regular patient care after an indication for Rezum treatment has been made independent of the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All male patients who are treated with Rezum due to prostate obstruction and LUTS in the participating study centers can be included if certain inclusion criteria are met and some exclusion criteria are not present.
  • The indication to perform Rezum needs to be made independently from the study. The decision for Rezum treatment is the responsibility of each individual practitioner and patient.
  • Age ≥ 18 years
  • Operated or supervision of surgery by a certified urologist
  • Subgroups of special interest are e.g. catheter-dependent patients, patients with oral anticoagulation, patients with preoperative urodynamic pressure-flow investigation (not older than 6 months) or patients with prostates bigger than 80 ml

Exclusion criteria

Exclusion Criteria:

  • Missing
  • Lack of ability to answer questionnaires due to laguage problems or mental incapacity (e.g. in dementia, mental disability)
  • Patient does not have a personal email address available and the survey cannot be completed via a relative's email address and the patient is not willing to complete the survey on the tablet at the clinic
  • Known or suspected neurogenic bladder dysfunction in e.g. Parkinson's disease, multiple sclerosis or other neurological diseases with possible effects on bladder function
  • History of malignant bladder tumor in the last two years (including CIS) or currently present malignant bladder tumor at time of Rezum treatment (including CIS)
  • Previous operation(s) on the prostate, except prostate , if this was performed more than 4 weeks ago at time of Rezum treatment
  • Previous operation(s) on the bladder neck
  • Presence of bladder neck stenosis requiring treatment at time of Rezum treatment
  • Planned combination of Rezum treatment concurrently with another urologic (*) or non-urologic procedure

(*) also the combination with a planned transurethral procedure is not allowed except for bladder stone removal

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Target follow-up
60 Months
Patient registry
Yes

Interventions

  • OtherCollection and evaluation of clinical (CROMs) and patient-reported outcomes (PROMs)

    The study uses a web-based German-language database (electronic data capture system, EDCS) called "REDCap" that provides both clinical reported outcome measures (CROMs) and patient-reported outcome measures (PROMs). PROMs are investigated by validated questionnaires: IPSS/QoL, ICIQ-MLUTS, MSHQ, ICIQ-MLUTSsex, QoR-15GE, PROMIS Global Health 10, ICIQ-S, NRS, and by home urine flow measurement (initially iUFlow, since October 2025 EmanoFlow ) as well as by self-designed questionnaires to assess patients´ preferences and expectations for Rezum and for surgical therapy of the prostate, satisfaction with the Rezum therapy, side effects of the Rezum therapy, (re)medication to treat BPO and LUTS, and reoperations after Rezum therapy.

  • OtherAnalysis of uroflowmetry data by EmanoFlow Mobile Application (App) and Emano Clinic Portal

    If patients have a smartphone with app function (Android or Apple), they will be provided with an FDA-registered home uroflowmetry mobile App (called EmanoFlow from Emano Metrics, USA) at study entry. This AI-based mobile application should enable patients to measure their urine flow conveniently from home and thus be independent of the medical consultation. EmanoFlow is marketed by Emano Metrics Inc., a Delaware C Corporation with its principal place of business at 132 East Broadway Suite 700, Eugene, OR, 97401, USA. Every time a patient is using the mobile App urine flow measurement data will be sent to the home uroflowmetry database (Emano Flow Clinic Portal).

06

What researchers measure

Primary outcomes

  1. Change in International Prostate Symptom Score/ Quality of Life (IPSS/ QoL)

    The IPSS is an eight-item validated questionnaire, consisting of seven symptom questions and one QoL question. The IPSS score is categorised as 'asymptomatic' (0 points), 'mildly symptomatic' (1-7 points), 'moderately symptomatic' (8-19 points), and 'severely symptomatic' (20-35 points).

    Time frame: At baseline, 6 weeks, 3 months, 6 months, 12 months and annually until the 5th follow-up year after treatment with Rezum

Secondary outcomes

  1. Change of maximum urinary flow rate (Qmax) measured by uroflowmetry

    Self-measured by patients at home using the iUFlow device (Kesem Health)

    Time frame: At baseline, 2 weeks, 6 weeks, 3 months, 6 months, 12 months and annually until the 5th follow-up year after treatment with Rezum

  2. Change of International Consultation on Incontinence Questionnaire for male lower urinary tract symptoms (ICIQ-MLUTS)

    The ICIQ-MLUTS is a widely used and validated patient-completed questionnaire including incontinence questions and bother for each symptom. It contains thirteen items (including incontinence questions and bother for each symptom), with subscales for nocturia and overactive bladder (OAB).

    Time frame: At baseline, 6 weeks, 3 months, 6 months, 12 months and annually until the 5th follow-up year after treatment with Rezum

  3. Change of Male Sexual Health Questionnaire (MSHQ)

    The MSHQ long form includes 3 domains: Erection scale (3 items), Ejaculation scale (7 items), Sexual satisfaction scale (6 items) (additional 2 items measuring bothersome linked to erection and ejaculation). Additional Items (Sexual Activity and Desire) are not to be collected.

    Time frame: At baseline, 6 weeks, 3 months, 6 months, 12 months and then annually until the 5th follow-up year after treatment with Rezum

  4. Change of International Consultation on Incontinence Questionnaire Male Sexual Matters Associated with Lower Urinary Tract Symptoms Module (ICIQ-MLUTSsex)

    The ICIQ-MLUTSsex is a patient-completed questionnaire for detailed evaluation of male sexual matters associated with their lower urinary tract symptoms and impact on quality of life (QoL). It is composed of 4 sections (erection, ejaculation, pain/discomfort during ejaculation, impact of urinary symptoms).

    Time frame: At baseline, 6 weeks, 3 months, 6 months, 12 months and then annually until the 5th follow-up year after treatment with Rezum

  5. Patient's postoperative recovery by QoR-15

    Investigation of type of anesthesia (general anesthesia, spinal anesthesia, local anesthesia, analgosedation) incl. reason for type of anesthesia and postoperative recovery using the validated German version of the Quality-of-Recovery-Score (QoR-15GE).

    Time frame: At baseline, at the first postoperative day and 2 weeks after treatment with Rezum

  6. Change in PROMIS Global Health 10 questionnaire

    Changes in Quality of Life associated with Rezum treatment using the PROMIS Global Health 10 questionnaire. It is a measure of overall health-related quality of life. The questionnaire consists of a combination of 10 questions that assess both the physical and mental health status of adult patients independent of their individual medical situation. The items are measured using a five-point response matrix that includes physical function, fatigue, pain, emotional distress and social health.

    Time frame: At baseline, 2 weeks, 6 weeks, 3 months, 6 months, 12 months and then annually until the 5th follow-up year after treatment with Rezum

  7. Change in ICIQ-S (International Consultation on Incontinence - Satisfaction)

    The ICIQ-S (International Consultation on Incontinence - Satisfaction) will be used to evaluate patient satisfaction after urological surgery. Question items consist of: outcome success, comparison of symptoms, return to "normal life", same situation, same choice, recommend, current symptoms, preparation for surgery, satisfaction of explanation, pain after surgery, satisfaction of pain relief, current pain, complications/side effects, result of surgery and satisfaction with surgery.

    Time frame: At 2 weeks, 6 weeks, 3 months, 6 months, 12 months and annually after treatment with Rezum

  8. Numeric pain Rating Scale (NRS)

    Investigation of patients' perception of pain during Rezum procedure in case of local anesthesia and/or analgosedation and after Rezum treatment using NRS. The NRS has the following scale: from 0 - 10 (no pain - worst pain imaginable).

    Time frame: At the first postoperative day

  9. Rezum side effects and Pain medication

    This questionnaire is self-designed. Typical side effects must be seen and investigated independently of treatment complications in order to provide patients with the best possible advice and information. The need for pain medication will be evaluated in a time context as well.

    Time frame: At baseline, 2 weeks, 6 weeks and 3 months

  10. Patients' preferences and expectations of Rezum Treatment

    This self-designed questionnaire considers measurement tools related to BPO/male LUTS treatment and aims to investigate patients' motivations, expectations and preferences for surgical desobstruction of the prostate due to BPO in general but also in particular concerning the Rezum treatment. This will attempt to better understand patient attitudes in order to improve future counseling of patients regarding minimally invasive procedures for the treatment of BPO-related male LUTS.

    Time frame: At baseline, 3 months, 6 months, 12 months and then annually until the 5th follow-up year after treatment with Rezum

  11. Questionnaire: BPO (BPH)/LUTS medication

    This self-designed questionnaire aims to evaluate the need for BPO (BPH)/LUTS medication.

    Time frame: At 2 weeks, 6 weeks, 3 months, 6 months, 12 months and then annually until the 5th follow-up year after treatment with Rezum

  12. Questionnaire: Reoperation

    This self-designed questionnaire aims to evaluate the need for urological reoperation.

    Time frame: At 3 months, 6 months, 12 months and then annually until the 5th follow-up year after treatment with Rezum

  13. Questionnaire: Bladder catheter

    This self-designed questionnaire aims to evaluate the need for bladder catheterization.

    Time frame: At 3 months, 6 months, 12 months and then annually until the 5th follow-up year after treatment with Rezum

  14. Number of steam injections and injection points during Rezum treatment

    Investigation of the influence of the number of steam injections and Injection points on outcome parameters, micturition parameters, sexual function, prostate size, side effects and complications.

    Time frame: At Baseline (on day of treatment with Rezum)

  15. Retreatment rate

    Number of retreatments (medical (drugs), bladder catheter and surgical) after Rezum treatment.

    Time frame: Up to 5 years after treatment with Rezum

  16. Surgical safety by classification of intraoperative adverse events (ClassIntra®)

    The classification defines intraoperative adverse events as any surgery or anesthesia-related deviation from the ideal intraoperative course occurring between begin of anesthesia and end of anesthesia. Surgical safety is investigated by analyzing intraoperative complications classified by ClassIntra (from Grade 0: No deviation from the ideal intraoperative course to Grade 5: Any deviation from the ideal intraoperative course with intraoperative death of the patient).

    Time frame: On day of treatment with Rezum

  17. 30-days postoperative complications by the Clavien-Dindo classification

    The classification defines postoperative adverse events occurring after the patient has left the recovery room until 30 days after surgery (from Grade I: Any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic and radiological intervention to Grade V: Death of a patient).

    Time frame: Within 30-days after treatment with Rezum

  18. Antimicrobial prophylaxis

    Investigation of the effectiveness of the chosen antimicrobial prophylaxis by analyzing the rate of postoperative symptomatic urinary tract infections (UTI) within the first 30 days after surgery as part of the Clavien-Dindo classification. Definition of symptomatic UTI is based on clinical diagnosis supported by measured bacteriuria of ≥105 cfu/ml treated with antimicrobial agents.

    Time frame: Within the first 30 days after treatment with Rezum

  19. Post voiding residual volume (PVR) measured by ultrasound

    Change of post voiding residual volume (PVR) measured by ultrasound is a simple test that can raise or lower the suspicion of bladder outlet obstruction (BOO).

    Time frame: Baseline and up to 5 years after treatment with Rezum

  20. Change of prostate size

    Measured by ultrasound or magnetic resonance imaging (MRI).

    Time frame: Baseline and up to 5 years after treatment with Rezum

  21. Change in bladder outlet obstruction index (BOOI)

    BOOI is represented by the equation: BOOI = Pdet @ Qmax - 2 x Qmax (Pdet = detrusor pressure; Qmax = maximum flow rate). BOOI \> 40 = obstructed; BOOI 20-40 = equivocal; and BOOI \< 20 = unobstructed.

    Time frame: Max. 6 months before Rezum and/or 3-6 months after Rezum treatment

  22. Change in bladder contractility index (BCI)

    The BCI is represented by the following formula: BCI = Pdet @ Qmax + 5 x Qmax. Using this formula, contractility can be divided into strong \> 150, normal 100-150, and weak \< 100.

    Time frame: Max. 6 months before Rezum and/or 3-6 months after Rezum treatment

  23. Change in International Prostate Symptom Score (IPSS) for detrusor (bladder muscle) overactivity (DO)

    Urodynamic analysis of detrusor overactivity (DO) during storage phase and correlation of pre- and postoperative DO with PROMs (IPSS). The IPSS is made up of 7 questions related to voiding symptoms. A score of 0 to 7 indicates mild symptoms, 8 to 19 indicates moderate symptoms and 20 to 35 indicates severe symptoms.

    Time frame: Max. 6 months before Rezum and/or 3-6 months after Rezum treatment

  24. MRI (magnetic resonance imaging) data

    MRI data not older than 12 months at time of Rezum treatment and MRI data in the follow-up period of 5 years are investigated in terms of prostate size, ablative lesions (lesions caused by Rezum) and PI-RADS (prostate imaging-reporting and data system) lesions.

    Time frame: Max. 12 months before Rezum and up to 5 years after treatment with Rezum

  25. Prostate cancer (PCa) detected by positive prostate biopsy

    The proportion of patients who receive Rezum treatment with a history of prostate cancer or who develop histologically confirmed prostate cancer during the post-treatment course.

    Time frame: Max 12 months and up to 5 years after treatment with Rezum

  26. Doctors' preferences, motivations and reasons to use Rezum

    Investigation of doctors' reasons for preference/choice of using Rezum in a patient using a self-designed questionnaire.

    Time frame: Before treatment with Rezum

  27. Change in ICIQ-Lower Urinary Tract Symptoms Quality of Life (ICIQ-MLUTS) score for detrusor (bladder muscle) overactivity (DO)

    Urodynamic analysis of detrusor overactivity (DO) during storage phase and correlation of pre- and postoperative DO with PROMs (ICIQ-MLUTS). The ICIQ-MLUTS is a questionnaire for evaluating male lower urinary tract symptoms and impact on quality of life (QoL). 1-84 overall score with greater values indicating increased symptom severity.

    Time frame: Max. 6 months before Rezum and/or 3-6 months after Rezum treatment

07

Study locations

16 of 19 sites recruiting
  • Universitätsklinikum Graz
    Graz, Austria
    Active, not recruiting

    Not enrolling at this site.

  • Alexianer St. Hedwig-Krankenhaus
    Berlin, 10115, Germany
    Recruiting
    • Tobias Bothmann, Dr · Contact
  • Universitätsklinikum Frankfurt
    Frankfurt, 60590, Germany
    Recruiting
    • Miriam Traumann, Dr · Contact
  • Universitätsklinikum Hamburg-Eppendorf (UKE),
    Hamburg, 20246, Germany
    Not yet recruiting
    • Philipp Gild, Dr. med · Contact
    • Dunja Diarra · Contact+49 40 7410 54836
  • Asklepios Westklinikum Hamburg GmbH
    Hamburg, 22559, Germany
    Recruiting
    • Guiseppe Magistro, PD Dr, med · Contact
  • Urologische Gemeinschaftspraxis Prüner Gang
    Kiel, 24103, Germany
    Recruiting
    • Christof van der Horst, MD · Contact+49 431 2604290
  • Krankenhaus Maria Hilf - Alexianer Krefeld
    Krefeld, 47805, Germany
    Recruiting
  • Klinikum Nürnberg
    Nuremberg, 90419, Germany
    Recruiting
  • Krankenhaus Reinbek St. Adolf Stift
    Reinbek, 21465, Germany
    Recruiting
    • Claus Brunken, Dr · Contact
  • Kliniken Sindelfingen
    Sindelfingen, 71065, Germany
    Recruiting
    • Johannes Dlugosch · Contact
    • Renate Endriss · Contact+49 7031-98 18968
  • Diakonie-Klinikum Stuttgart Diakonissenkrankenhaus und Paulinen gGmbH
    Stuttgart, 70176, Germany
    Not yet recruiting
    • Daniel Seidl, Dr · Contact
    • Sabine Nuding · Contact+49 711 991-3517
  • Kantonsspital Aarau
    Aarau, Aarau 5001, Switzerland
    Recruiting
    • Lukas Prause, Dr.med.univ. · Contactlukas.prause@ksa.ch · +41 62 838 47 59
    • Lukas Prause, Dr.med.univ. · Principal investigator
  • Hirslanden Klinik St. Anna
    Lucerne, Canton of Lucerne 6006, Switzerland
    Recruiting
    • Felix Moltzahn, Dr. med. · Contactfelix.moltzahn@hin.ch · +41 41 410 4170
    • Felix Moltzahn, Dr. med. · Principal investigator
  • University Hospital Basel, Department of Urology
    Basel, 4031, Switzerland
    Recruiting
    • Jan Ebbing, PD Dr. med. · ContactSteamOne.urologie@usb.ch · +41 61 328 56 59
    • Jan Ebbing, PD Dr. med. · Principal investigator
  • Inselspital Bern
    Bern, 3010, Switzerland
    Recruiting
    • Karl-Georg Sommer, Dr. med · Contact
    • Anselm Lafita · Contact+41 31 632 23 32
  • Kantonsspital Luzern
    Lucerne, Switzerland
    Recruiting
  • Uroviva AG
    Rothrist, 4852, Switzerland
    Recruiting
    • Andrej Panic, Dr · Contact+41 41 934 00 73
  • Kantonsspital St. Gallen
    Sankt Gallen, Switzerland
    Recruiting
    • Olivia Köhle, MD · Contact+41 71 494 14 16
  • Universitätsspital Zürich
    Zurich, 8091, Switzerland
    Recruiting
    • Etienne Xavier Keller, Dr. med · Contact
    • Alexandra Uster · Contact+41 44 255 54 26
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Dec 2031, 108 months after the start.

Of 57 non-industry observational studies under Lower Urinary Tract Symptoms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 70. This study's planned 108 months is above that.

Counting every sponsor, half of 63 studies reached it within 33 months; a quarter within 11 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2022
First posted
Aug 10, 2022
StartActual
Dec 16, 2022
Primary completionEst.
Dec 2031
CompletionEst.
Dec 2031
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 2 sites removed
Show 2 added (2 Switzerland)
  • Kantonsspital Aarau · Aarau, Switzerland
  • Hirslanden Klinik St. Anna · Lucerne, Switzerland
Show 2 removed
  • Kantonsspital Aarau · Aarau, Switzerland
  • Hirslanden Klinik St. Anna · Lucerne, Switzerland
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    2 sites added, 2 sites removed
    Show 2 added (2 Switzerland)
    • Kantonsspital Aarau · Aarau, Switzerland
    • Hirslanden Klinik St. Anna · Lucerne, Switzerland
    Show 2 removed
    • Kantonsspital Aarau · Aarau, Switzerland
    • Hirslanden Klinik St. Anna · Lucerne, Switzerland
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05495633
Responsible party
Sponsor
First posted
Aug 10, 2022
Start date
Dec 16, 2022
Primary completion
Dec 2031 (estimated)
Completion
Dec 2031 (estimated)
Last update
Oct 20, 2026

Study contacts

Niklas Simon, Study Coordinator
Contact
Niklas.Simon@usb.ch
+41 615565616
Heike Püschel, study nurse
Contact
SteamOne.urologie@usb.ch
+41 61 556 54 77
Felix Wieland, Dr. med.
principal investigator · University Hospital Basel, Department of Urology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion